Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading AMRN daily closes…
Loading price history…
Pipeline assets
Icosapent ethyl
Approved · Active
Aliases VASCEPA, VAZKEPA
Partnerships Seven commercial partners: Edding (China Territory — $25M Recordati-style; tiered double-digit royalties, up to $120M sales milestones), HLS Therapeutics (Canada — up to $47.5M sales milestones + tiered royalties), Biologix (MENA), CSL (Australia/New Zealand), Recordati (59 European countries, Jun 2025 — $25M upfront, up to $150M sales milestones + royalties), Neopharm (Israel), Lotus (ASEAN); Mochida (Jun 2018 collaboration to research/develop new EPA-based products and indications — still early stages, no named asset)
Indications
Severe hypertriglyceridemia (MARINE indication)(Approved)
CV risk reduction in statin-treated high-risk patients (REDUCE-IT indication)(Approved)
Status note Single commercial product; no clinical-stage pipeline in the filing. U.S. FDA approved Jul 2012 (MARINE) and Dec 2019 (REDUCE-IT); EC approved Mar 2021 as VAZKEPA. Several MARINE-indication patents invalidated Mar 2020 (Nevada court; appeals exhausted); generics from Dr. Reddy's and Hikma approved for MARINE indication in U.S.
Per-asset detail extracted from the 10-Q filed 2026-07-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.